Fortitude
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
Description: This double-blind trial assesses the effectiveness of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in patients Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information